United States Secondary Myelofibrosis Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Secondary Myelofibrosis Market growing with a CAGR of 6% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/secondary-myelofibrosis-market?sb

Key Development:

United States: Recent Secondary Myelofibrosis Developments

✅ In December 2025, novel clinical insights from ASH 2025 highlighted emerging combination therapies for myelofibrosis, including pelabresib with ruxolitinib showing durable spleen volume reduction and symptom relief, underscoring new avenues for patients beyond standard JAK inhibitors.

✅ In September 2025, Karyopharm Therapeutics completed enrollment for its Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib in myelofibrosis patients a key milestone ahead of anticipated 2026 results that could influence therapeutic strategy.

✅ In July 2025, Sumitomo Pharma America's investigational oral PIM1 kinase inhibitor nuvisertib (TP‐3654) received FDA Fast Track designation for the treatment of intermediate‐ or high‐risk myelofibrosis, reflecting progress toward future therapy options for relapsed/refractory patients.

✅ In June 2025, the U.S. FDA granted Fast Track designation to nuvisertib for myelofibrosis, aiming to accelerate development of this novel kinase‐targeting approach after promising early clinical data were presented at EHA 2025.

Japan: Recent Secondary Myelofibrosis Developments

✅ In July 2025, the Ministry of Health, Labour and Welfare (MHLW) in Japan continued to support innovative MF drug development, with orphan drug designation previously granted to Sumitomo Pharma's nuvisertib, reinforcing Japan's role in global myelofibrosis R&D alongside FDA Fast Track status.

✅ In June 2025, clinical discussions and research presented at medical congresses in Japan emphasized expanded use of JAK inhibitors and new molecular approaches in myeloproliferative neoplasms, including strategies relevant to myelofibrosis care pathways.

✅ In June 2024 (still relevant to recent regulatory landscape), Japan's MHLW granted approval for momelotinib (brand Omjjara) to treat myelofibrosis encompassing both primary and secondary forms offering an orally administered option targeting anemia and splenomegaly based on comprehensive phase 3 MOMENTUM and SIMPLIFY‐1 data.

✅ In late 2024/early 2025, ongoing research collaborations in Japan have contributed to international clinical trial data on myelofibrosis, reinforcing the nation's contributions to evolving care standards and future therapeutic innovation.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=secondary-myelofibrosis-market

Key Players:

=> Novartis Pharma AG, MANUS AKTTEVA BIOPHARMA LLP, Bristol-Myers Squibb, GNH India Pharmaceuticals Limited, CTI BIOPHARMA CORP., Dr. Reddy's Laboratories, Incyte Corporation, Pfizer Inc., GlaxoSmithKline Pharmaceuticals Ltd, Anant Pharmaceuticals Pvt Ltd among others.

Key Segments:

By Treatment

Based on Therapy - ~40% share

Includes targeted therapies, immunotherapies, and combination treatments; widely adopted in hospitals and specialty clinics for personalized treatment approaches.

Based on Bone Marrow Transplantation - ~30% share

High-cost, specialized treatment; primarily concentrated in advanced hospitals and research institutes with transplant facilities.

Based on Drugs - ~30% share

Covers chemotherapeutic, supportive care, and novel drug therapies; strong uptake in hospital pharmacies and specialty clinics.

By End User

Hospitals - ~50% share

Major adoption for inpatient care, therapy administration, and drug-based treatments; central to market growth.

Specialty Clinics - ~20% share

Focused adoption for specific therapy types and outpatient treatment; growing role in niche and personalized care.

Academic and Research Institutes - ~15% share

Conduct clinical trials, research-based therapies, and bone marrow transplantation studies; strategic for innovation and pipeline development.

Others - ~15% share

Includes homecare services, government treatment centers, and emerging outpatient care providers.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/secondary-myelofibrosis-market?sb

By Region

North America - ~40% share

U.S. - Largest market driven by advanced healthcare infrastructure, R&D, and high adoption of bone marrow and targeted therapies.

Canada, Mexico - Moderate adoption through specialty clinics and hospital networks.

Europe - ~25% share

Germany, U.K., France, Italy - Strong presence in hospitals and academic centers; bone marrow transplant facilities concentrated in select countries.

Rest of Europe - Growing adoption of drug-based treatments and therapy-driven approaches.

South America - ~10% share

Brazil, Argentina - Emerging adoption in hospitals and specialty clinics; limited access to high-cost bone marrow treatments.

Rest of South America - Gradual growth in hospital-administered therapies.

Asia Pacific - ~20% share

China, India, Japan, South Korea - Rapid adoption of therapy-based treatments; bone marrow transplantation growing in major hospitals.

Rest of Asia Pacific - Expanding hospital infrastructure supports drug-based treatment growth.

Middle East & Africa - ~5% share

Concentrated in leading hospitals; therapy- and drug-based treatments dominate due to limited access to advanced bone marrow transplantation facilities.

FAQ

Q: What is the growth rate of the Secondary Myelofibrosis Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.